Which off-label category is listed for dementia management?

Which off-label category is listed for dementia management?

• A. Antihistamines
• B. Stimulants
• C. Beta blockers
• D. Acetylcholinesterase inhibitors

Answer: (D)

Dementia management often hinges on boosting cholinergic signaling because loss of acetylcholine contributes to cognitive decline. Acetylcholinesterase inhibitors block the enzyme that breaks down acetylcholine, increasing its levels in the brain. This can improve memory, orientation, and daily functioning in many patients with Alzheimer's disease and some other dementias, making this the most appropriate pharmacologic category for symptomatic management. The other options don’t target cognition in the same beneficial way: antihistamines tend to be anticholinergic and can worsen cognitive function; stimulants are not standard dementia therapy and carry risks; beta blockers are not used to enhance cognition.

Dementia management often hinges on boosting cholinergic signaling because loss of acetylcholine contributes to cognitive decline. Acetylcholinesterase inhibitors block the enzyme that breaks down acetylcholine, increasing its levels in the brain. This can improve memory, orientation, and daily functioning in many patients with Alzheimer's disease and some other dementias, making this the most appropriate pharmacologic category for symptomatic management. The other options don’t target cognition in the same beneficial way: antihistamines tend to be anticholinergic and can worsen cognitive function; stimulants are not standard dementia therapy and carry risks; beta blockers are not used to enhance cognition.